Aptorum Group Limited reported its financial results for the fiscal year ended December 31, 2024. The company recorded zero total revenue and a gross profit of zero, reflecting its status as a clinical-stage biopharmaceutical company with no commercialized products generating sales.
For the fiscal year, Aptorum Group incurred an operating income of -3.00 million and a net income of -4.27 million. Research and development expenses amounted to 2.20 million, while selling, general, and administrative expenses were 1.46 million, indicating significant investment in pipeline development.
As of December 31, 2024, the company's balance sheet showed cash and cash equivalents of 874,238, with total debt at 3.35 million and total equity at 21.13 million. The accumulated deficit, reflected in retained earnings, stood at -72.43 million, highlighting the substantial capital required for drug development. Cash flow from operating activities for 2024 was -1.19 million, resulting in a free cash flow of -1.19 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.